Analysts See Daiichi Sankyo Exercising Light Control Of Ranbaxy
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Japan's Daiichi Sankyo will let the current management of India's top drug firm Ranbaxy Laboratories have a free hand in pursuing new ties-ups and expanding generic sales globally following the model set by Novartis-Sandoz, analysts say
You may also be interested in...
Analysts Say Ranbaxy Management Would Likely Rebuff Any Pfizer Offer
NEW DELHI - A hostile bid by the world's largest drug maker Pfizer to thwart a deal for a majority stake by Japan's Daiichi Sankyo in India's top generic firm Ranbaxy Laboratories would likely be rebuffed by management led by the Singh family, which holds nearly 35 percent of the firm, analysts said
Analysts Say Ranbaxy Management Would Likely Rebuff Any Pfizer Offer
NEW DELHI - A hostile bid by the world's largest drug maker Pfizer to thwart a deal for a majority stake by Japan's Daiichi Sankyo in India's top generic firm Ranbaxy Laboratories would likely be rebuffed by management led by the Singh family, which holds nearly 35 percent of the firm, analysts said
Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs
NEW DELHI - Japan's Daiichi Sankyo will buy a majority stake in India's top drug maker in a deal that will vault the combined operations into the top 15 pharmaceutical firms globally and end the founding Singh family's role as largest shareholder of Ranbaxy Laboratories